Iván Márquez‐Rodas
Hospital General Universitario Gregorio Marañón(ES)Centro de Investigación Biomédica en Red de Cáncer(ES)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
- → Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial(2018)1,385 cited
- → Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial(2017)763 cited